Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Portside Wealth Group LLC

Portside Wealth Group LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the first quarter, HoldingsChannel.com reports. The firm owned 16,481 shares of the biopharmaceutical company’s stock after selling 780 shares during the period. Portside Wealth Group LLC’s holdings in Gilead Sciences were worth $1,847,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of GILD. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in shares of Gilead Sciences by 4.1% during the fourth quarter. Chicago Partners Investment Group LLC now owns 7,129 shares of the biopharmaceutical company’s stock worth $635,000 after purchasing an additional 279 shares during the period. Spire Wealth Management lifted its position in shares of Gilead Sciences by 9.1% in the 4th quarter. Spire Wealth Management now owns 15,560 shares of the biopharmaceutical company’s stock worth $1,437,000 after buying an additional 1,295 shares during the last quarter. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. Finally, Princeton Global Asset Management LLC grew its position in shares of Gilead Sciences by 400.0% during the 4th quarter. Princeton Global Asset Management LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 400 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GILD shares. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, Piper Sandler boosted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $109.33 on Wednesday. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96. The firm has a market cap of $136.00 billion, a P/E ratio of 295.49, a PEG ratio of 0.71 and a beta of 0.26. The stock has a fifty day moving average price of $105.45 and a two-hundred day moving average price of $101.10. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,929 shares of company stock valued at $6,748,980 in the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.